Japanese encephalitis vaccine - Shandong Hengye BiotechAlternative Names: Vero cell-derived inactivated Japanese encephalitis vaccine - Shandong Hengye Biotech
Latest Information Update: 19 Sep 2016
At a glance
- Originator Shandong Hengye Biotech
- Developer Jiangsu Provincial Center for Disease Control and Prevention; Shandong Hengye Biotech
- Class Viral vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Japanese encephalitis
Most Recent Events
- 01 Oct 2014 Phase-III clinical trials in Japanese encephalitis (In infants, Prevention) in China (Parenteral)